Key Takeaways
- Pembrolizumab combined with paclitaxel-carboplatin significantly improves progression-free survival in patients with advanced/recurrent endometrial cancer, regardless of mismatch repair (MMR) status
- Although overall survival data are immature, trends favor pembrolizumab, particularly in MMR-deficient patients
- These findings bolster pembrolizumab’s role as a front-line therapeutic option for advanced-stage endometrial cancer
A groundbreaking phase 3 clinical trial, NRG GY018, has revealed new hope for patients with advanced-stage or recurrent endometrial cancer, a population historically treated with paclitaxel-carboplatin chemotherapy alone. The addition of pembrolizumab, a widely used immunotherapy, to the chemotherapy regimen has shown significant improvements in progression-free survival (PFS), regardless of mismatch repair (MMR) status.
The trial enrolled 810 women aged ≥18 years with newly diagnosed stage III or IVA endometrial cancer with measurable disease, or stage IVB/recurrent disease with or without measurable disease. Participants were randomized to receive either pembrolizumab plus paclitaxel-carboplatin or placebo plus the same chemotherapy regimen, followed by maintenance pembrolizumab or placebo for up to 24 months.
The results were striking. Investigator-assessed PFS, the primary endpoint, strongly favored pembrolizumab. For MMR-proficient patients, pembrolizumab reduced the risk of disease progression or death by 36% (hazard ratio [HR], 0.64; P=.0008). MMR-deficient patients saw an even greater benefit, with a 55% reduction in risk (HR, 0.45; P=.0005). These findings validate pembrolizumab as an effective addition to first-line therapy for this challenging cancer population.
While overall survival data remain immature, hazard ratios suggest a promising trend in favor of pembrolizumab. For MMR-proficient patients, the HR for death was 0.79, and for MMR-deficient patients, it was 0.55. Although statistical significance wasn’t reached, these exploratory analyses hint at potential survival benefits.
For oncology teams, these results offer actionable insights. Pembrolizumab plus chemotherapy represents a paradigm shift in the treatment of advanced endometrial cancer, providing patients with an effective option that may delay disease progression and potentially extend survival. Importantly, this approach applies across MMR statuses, broadening its applicability to a wide range of patients.
Clinicians should also note that the trial underscored pembrolizumab’s role as a maintenance therapy, allowing continued immune system activation even after the completion of chemotherapy cycles. This strategy may further enhance long-term outcomes while maintaining manageable toxicity profiles.
As the field of endometrial cancer treatment evolves, the NRG GY018 trial highlights the importance of integrating immunotherapy into frontline care. Oncology teams can now offer patients a therapeutic option that not only improves clinical outcomes but also aligns with the growing emphasis on personalized, biomarker-driven treatment strategies.
Source: Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med. 2025;31:1539-1546.
